K071776

SECTION 4

510K SUMMARY

NAME OF FIRM:

Codman & Shurtleff, Inc.

325 Paramount Drive

Raynham

MA 02767-0350

JUL 2 6 2007

510(k) CONTACT:

Rachel Creane

Senior Regulatory Affairs Specialist

TRADE NAME:

Aneuroplastic[®]

COMMON NAME:

Methyl Methacrylate (MMA)

CLASSIFICATION:

Class II; 21 CFR 882.5030

DEVICE PRODUCT CODE:

JXH

SUBSTANTIALLY EQUIVALENT

DEVICES:

Aneuroplastic® (K873688)

SmartSet GMV Endurance Gentamicin Bone Cement

(K033382)

DEVICE DESCRIPTION:

Aneuroplastic[®] is a self-curing methylmethacrylate (MMA) resin for reinforcing and encapsulating cerebral aneurysms. The following modifications are being made:

A change is being made to the formulation of the liquid component and the Instructions for Use (IFU) is being updated.

INTENDED USE AND INDICATIONS:

Aneuroplastic® is indicated for the reinforcing and encapsulating of cerebral aneurysms.

BASIS OF SUBSTANTIAL EQUIVALENCE:

The substantial equivalence of Aneuroplastic[®] to the identified predicate devices is demonstrated by its similarity in terms of technological characteristics (chemical composition, material properties, performance characteristics, manufacture, packaging and sterilization) to Aneuroplastic[®] (K873688) and SmartSet GMV Endurance Gentamicin Bone Cement (K033382).







Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUL 2 6 2007

Codman & Shurtleff, Inc. % Ms. Rachel Creane Senior Regulatory Affairs Specialist 325 Paramount Drive Raynham, Massachusetts 02767-0350

Re: K071776

Trade/Device Name: Aneuroplastic[®] Regulation Number: 21 CFR 882.5030

Regulation Name: Methyl methacrylate for aneurysmorrhaphy

Regulatory Class: II Product Code: JXH Dated: June 28, 2007 Received: July 2, 2007

Dear Ms. Creane:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Ms. Rachel Creane

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours

Mark N. Melkerson

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

SECTION 5

INDICATIONS STATEMENT

510(k) Number (if known):		
Device Name: Aneuroplastic®		
Indications for Use:		
Aneuroplastic® is indicated for the reinfor	cing and encapsula	ating of cerebral aneurysms.
Prescription Use	OR	Over-The Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)		
Concurrence of CDRH, Office of Device Evaluation (ODE)		
Much 110	Milleur -	Page 1 of
(Division Sign-Off) Division of General, Re and Neurological Device	es	
510(k) Number VC	1717+6	